A Skeletal Muscle Ryanodine Receptor Interaction Domain in Triadin by Wium, Elize et al.
A Skeletal Muscle Ryanodine Receptor Interaction
Domain in Triadin
Elize Wium, Angela F. Dulhunty, Nicole A. Beard*
John Curtin School of Medical Research, Australian Capital Territory, Australia
Abstract
Excitation-contraction coupling in skeletal muscle depends, in part, on a functional interaction between the ligand-gated
ryanodine receptor (RyR1) and integral membrane protein Trisk 95, localized to the sarcoplasmic reticulum membrane.
Various domains on Trisk 95 can associate with RyR1, yet the domain responsible for regulating RyR1 activity has remained
elusive. We explored the hypothesis that a luminal Trisk 95 KEKE motif (residues 200–232), known to promote RyR1 binding,
may also form the RyR1 activation domain. Peptides corresponding to Trisk 95 residues 200–232 or 200–231 bound to RyR1
and increased the single channel activity of RyR1 by 1.4960.11-fold and 1.860.15-fold respectively, when added to its
luminal side. A similar increase in [3H]ryanodine binding, which reflects open probability of the channels, was also observed.
This RyR1 activation is similar to activation induced by full length Trisk 95. Circular dichroism showed that both peptides
were intrinsically disordered, suggesting a defined secondary structure is not necessary to mediate RyR1 activation. These
data for the first time demonstrate that Trisk 959s 200–231 region is responsible for RyR1 activation. Furthermore, it shows
that no secondary structure is required to achieve this activation, the Trisk 95 residues themselves are critical for the Trisk
95-RyR1 interaction.
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Introduction
Triadins are a family of proteins consisting of 6 known isoforms,
all of which are splice variants of the same gene [1,2,3]. Four
triadin skeletal (Trisk) isoforms have been identified, namely Trisk
32, Trisk 49, Trisk 51 and the longer 95 kDa Trisk 95 [1,2,3,4,5].
Two cardiac triadin isoforms are described, the predominantly
expressed triadin-1 isoform (which forms a doublet of 35 and
40 kDa) and triadin-3 (75 kDa) [6]. All isoforms share an identical
short N-terminal domain and single transmembrane domain, but
differ in length in the C-terminal region [6,7,8]. Trisk 95 was first
identified as a disulfide-linked transmembrane protein located
within the junctional sarcoplasmic reticulum (SR) [1,2,3], which
co-localized with the Ca2+ release complex in skeletal muscle. The
skeletal Ca2+ release complex is a large macromolecular complex,
stretching from the surface membrane of the muscle cell, through
to the SR, the internal Ca2+ store. Central to this complex is
a ligand-gated Ca2+ release channel, the ryanodine receptor (RyR),
which is a 2.2 MDa homotetrameric channel embedded in the SR
membrane. The skeletal RyR (RyR1) has recruited the dihydro-
pyridine receptor (DHPR) as a voltage sensor and the skeletal Ca2+
binding protein calsequestrin (CSQ1) as a SR Ca2+ sensor. RyR1-
dependent Ca2+ release, initiated by the DHPR response to an
action potential, is modified by a variety of factors including ions,
co-proteins and the Ca2+ environment within the SR lumen. The
luminal Ca2+ environment is detected and communicated to RyR1
by a complex of proteins found in the SR. CSQ1 is the major Ca2+
binding protein which senses and communicates the level of free
Ca2+ inside the SR to the RyR1 [9,10,11]. CSQ’s location close to
RyR1 allows such communication, yet CSQ1 does not bind to
RyR1 directly. Instead, the CSQ1-RyR1 interaction has been
thought to be mediated by Trisk 95 and another structurally similar
protein, junctin [12,13,14,15]. Whilst Trisk 95 binds both CSQ1
and RyR1 [15,16,17], it does not support the functional CSQ1-
RyR1 interaction [13]. Rather, Trisk 95 is deemed to facilitate the
orthograde signal between the DHPR and RyR1 in excitation-
contraction coupling (EC-coupling) [18]. Results from siRNA-
mediated triadin knockdown [19] and pan-triadin-knockout studies
[20] support these findings. It should be noted that triadin knockout
mice show normal skeletal contractility, which may be due to
a contribution from numerous compensatory mechanisms [21].
Various regions on Trisk 95 and junctin have been reported to
be responsible for association with RyR1 and CSQ1 in the
junctional SR [14,17,18,22]. Trisk 95 association with RyR1 in
the SR lumen increases channel activity in lipid bilayers [13]. The
binding domain on RyR1 for Trisk 95 has been localized to three
residues (D4878, D4907, and E4908) on the M8/M10 luminal loop of
RyR1, flanking the pore helix [18,23]. In vitro binding studies
[17,22] have shown that several regions of Trisk 959s luminal
domain can bind to RyR1, with residues 200–232 [17] and
2672280 [22] of the rabbit isoform identified as putative RyR1
binding targets. However, it has remained unclear whether either
or both regions are required for RyR1 activation by Trisk 95. Of
these Trisk 95 regions, only 200–232 exists in the much shorter
cardiac triadin –1 isoform and the residues are homologous
between the two isoforms.
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Given that luminal addition of Trisk 95 to RyR1 and luminal
addition of triadin-1 to RyR2 induce activating responses in the
channels [24,25], it is likely that a region common to both triadin
isoforms is responsible for their interactions with RyR1 and RyR2.
Thus we have specifically investigated the interaction of Trisk 95
residues 200–232 with RyR1.
The skeletal 200–232 region contains a KEKE motif, which
promotes protein association [12,26,27,28]. KEKE motifs are
defined as sequences greater than 12 amino acids which lack W, Y,
F, P and five positive or negatively charged residues in a row. They
must also contain more than 60% K and E/D residues [29]. The
Trisk 95 200–232 KEKE motif has been predicted to fold into a b-
strand in canine cardiac triadin-1, causing most E and K residues
to align and form a polar surface on one side of the strand [26,27].
The charged side chains of these residues may then form hydrogen
bonds with charged residues on protein binding partners, creating
a ‘‘polar zipper’’ between the proteins [18,23,27]. Curiously in
triadin-1, residues found within this KEKE motif have been
identified as the binding site for cardiac CSQ (CSQ2; [27]). Given
the high sequence homology between CSQ1 and CSQ2, it is
possible that CSQ1 also binds to the KEKE motif on Trisk 95
(208–232).
In this manuscript we examine the KEKE motif at residues
200–232 of Trisk 95 and the ability of this region to bind to and
regulate RyR1 activity. We find that residues 200–231 of Trisk 95
are able to activate RyR1 in the same way as full length Trisk 95.
These results show for the first time that these 31 residues are
sufficient to support the regulatory actions of Trisk 95 on RyR1.
Materials and Methods
Materials
The monoclonal 34C anti-RyR antibody and monoclonal
VIIID12 anti-CSQ1 antibody were from Abcam (Cambridge,
MA, USA). Monoclonal anti-triadin (clone IIG12) was from Sigma
Aldrich, Inc (Saint Louis, MO, USA), polyclonal anti-junctin
antibody was produced against a small N-terminal peptide by
IMVS pathology (Adelaide, SA, Australia) and all IgG HRP
secondary antibodies were from Santa Cruz (Santa Cruz, CA,
USA). Phospholipids were from Avanti Polar Lipids (Alabaster,
AL, USA). Streptavidin-agarose was from Thermoscientific
(Rockford, IL, USA). SDS PAGE apparatus and consumables
were from Bio-Rad (Gladesville, NSW, Australia). All other
chemicals were obtained from Sigma-Aldrich (Castle Hill, NSW,
Australia).
SR Vesicle Isolation and RyR1 Purification
SR vesicles were prepared from back and leg skeletal muscle
isolated from New Zealand rabbits [30]. RyRs were solubilized
and purified as described previously [31]. The purified RyR1 was
concentrated, snap-frozen and stored at 270uC. The protein was
resolved on SDS polyacrylamide gels. Following Western Blot, the
purity of the solubilized RyR1 fraction was determined by
immunoprobing with anti-RyR1, anti-CSQ, anti-triadin and
anti-junctin antibodies to detect contamination by these proteins.
RyR1 DM1,2,3 Mutant Protein Expression
HEK-293T cells were transfected with a mammalian expression
vector, pCIneo, encoding the GFP tagged RyR1 DM1,2,3 mutant
using calcium phosphate precipitation. RyR1 DM1,2,3 contains
three alanine substitution mutations; D4878A, D4907A and
E4908A and was kindly provided by Professor R. Dirksen [18].
Forty eight hours post-transfection cells were homogenized in
homogenizing buffer (300 mM sucrose, 5 mM imidazole, pH 7.4)
using an IKA Ultra-Turrax T10 homogeniser (IKA Works (Asia)
Sdn Bhd, Selangor, Malaysia) before centrifuging at 751306 g for
2 h at 4uC. The resultant pellet was further homogenized
manually in homogenizing buffer using a glass homogenizer and the
presence and purity of RyR1 DM1,2,3 was assessed using SDS
PAGE and Western Blot.
Electrophoresis and Western Blot
SDS-PAGE and Western Blot are described in [32].
Peptide Synthesis
Peptides corresponding to the 200–232 and 200–231 residue
sequence of Trisk 95 [18] were obtained from the Biomolecular
Resource Facility, The John Curtin School of Medical Research
(Canberra, ACT, Australia). Peptides were synthesized using the
9-fluorenylmethyloxycarbonyl method on a CEM Microwave-
assisted Peptide Synthesizer (CEM Corporation; Matthews, NC,
USA) and purified by one round of C18 reversed-phase HPLC. As
Figure 1. Triadin200–232 and triadin200–231 peptides bind to
RyR1 and exhibit a disordered secondary structure. (A) Circular
dichroism spectra averaged from four scans and corrected for the
10 mM sodium phosphate buffer are shown. Both triadin peptides
(triadin200–231 (black trace) and triadin200–232 (grey trace); 0.03 mg/ml)
show a negative peak at ,197 nm, consistent with an intrinsically
disordered structure. A positive peak at ,190 nm and negative peaks
at ,208 and ,223 nm (indicative of a-helical secondary structure) or
a positive peak at ,195 nm and a negative peak at ,217 nm
(indicative of b-sheet secondary structure), are absent. (B) Western
blot, following streptavidin-agarose affinity chromatography, showing
the association of RyR1 with biotin tagged triadin peptide. The upper
half of the membrane was probed with anti-RyR1 antibody and the
lower half was probed with Streptactin-HRP conjugate to identify the
biotin tagged peptides. Lane 1 protein sample eluted from streptavidin-
agarose incubated with RyR1 alone; Lane 2 purified RyR1 alone
(control); Lane 3 biotin tagged triadin200–231 peptide alone (control);
Lanes 4 and 5 protein sample eluted from streptavidin-agarose affinity
chromatography, where streptavidin-agarose was incubated with biotin
tagged triadin200–232 or triadin200–231 peptide respectively, prior to
incubation with RyR1.
doi:10.1371/journal.pone.0043817.g001
Triadin-RyR Interaction Domain
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required, the N-terminus was protected by acetylation. The
RyR14871–4910 peptide, containing the putative Trisk 95 binding
domain on the RyR1 [18], was produced and HPLC purified by
GL Biochem (Shanghai) Ltd (Shanghai, China). Peptide purity was
confirmed using mass spectroscopy. The peptide sequences are as
follows:
Triadin200–232 peptide: 200KTVTKEEKKARTKEKIEEKTK-
KEVKGVKQEKVK
232
.
Triadin200–231 peptide: 200KTVTKEEKKARTKEKIEEKTK-
KEVKGVKQEKV
231
.
RyR14871–4910 peptide: 4871EPDMKCDDMMTCYLFH-
MYVGVRAGGGIGDEIEDPAGDEYE
4910
.
For affinity chromatography a biotin tag was conjugated to the
N-terminal end of the triadin200–232 and triadin200–231 peptides. A
linker sequence of 4 residues (KPET), corresponding to residues
196–199 of rabbit skeletal Trisk 95, was included between the
biotin tag and peptide sequence to minimize the risk of the biotin
tag interfering with the binding domain for the RyR1.
Circular Dichroism
Circular Dichroism (CD) spectra of the peptides were obtained
using a Chirascan spectrometer (Applied Photophysics, Surrey,
UK) held at 20uC by a Melcor Peltier temperature controller.
Peptides were diluted to 0.03 mg/ml in a buffer composed of
10 mM di-sodium hydrogen orthophosphate dihydrate and
10 mM sodium dihydrogen orthophosphate monohydrate
(pH 8.0), and spectra were recorded between 180 nm and
240 nm in a 0.1 cm path length cell. Each spectrum was averaged
from 4 scans and corrected for buffer absorbance.
Streptavidin-agarose Affinity Chromatography
Briefly, biotinylated peptides (2 mg/ml in affinity buffer contain-
ing 150 mM NaCl, 20 mM MOPS and 1 mM CaCl2 at pH 7.4)
were coupled to 200 ml streptavidin-agarose and incubated by
rotation for 3 h at room temperature or 4uC overnight. Unbound
peptide was removed by centrifugation and the streptavidin-
agarose-peptide slurry was washed 5 times with 56bed volume of
affinity buffer. Purified RyR1 (25 ml of 1 mg/ml in affinity buffer) was
pre-cleared in streptavidin-agarose with rotation overnight at 4uC,
to eliminate non-specific binding, and the supernatant (pre-cleared
RyR1) was incubated with the streptavidin-agarose-peptide slurry
with rotation overnight at 4uC. The streptavidin-agarose-peptide-
RyR1 slurry was washed in affinity buffer as above. Proteins and
peptides were eluted from the streptavidin-agarose by boiling the
samples in sample buffer (200 mM Tris HCl (pH 6.8), 20% b-
mercaptoethanol, 40% glycerol, 8% SDS, and 0.08% bromophe-
nol blue) for 5 min. Proteins and peptides were identified by
immunoprobing with anti-RyR antibody and streptactin (to detect
biotinylated peptides) after SDS PAGE and Western Blot.
[3H]ryanodine Binding
[3H]ryanodine binding was performed as described in [18],
except that 5 mg of purified RyR1 and 63 nM of triadin peptide
were used. In experiments where triadin was pre-incubated with
RyR14871–4910 peptide, 630 nM RyR14871–4910 peptide was used
to saturate triadin. [3H]ryanodine binds to the RyR preferentially
when it is in its open state and binding is an indicator of RyR1
activity [33].
Figure 2. Triadin peptides modulate purified RyR1. (A) Running histogram of a typical bilayer experiment. Open probability (Po) was measured
every 30 s throughout the lifetime of the experiment before and after the addition of 63 nM and then 252 nM triadin200–231 peptide (arrows) at
+40 mV (light grey bins) and 240 mV (dark grey bins). Data averages for each condition are shown as horizontal broken lines for +40 mV and
240 mV, and median is presented as a horizontal solid line. (B, C) 3 s traces of purified RyR1 channel activity. Activity was recorded at +40 mV (left)
where channels are opening upward from zero current (c, continuous line) to maximum open conductance (o, broken line) and at 240 mV (right),
where channel openings are downwards from zero current (c, continuous line) to maximum open conductance (o, broken line). Top panel – control
recording of purified RyR1 prior to the addition of triadin peptide; middle and bottom panel – after the addition of 63 nM and 252 nM triadin peptide
to the trans chamber. (B) Shows addition of triadin200–232 peptide, and (C) shows addition of triadin200–231. Control Po in the absence of peptide was
0.4660.12 at +40 mV and 0.3860.17 at 240 mV (for triadin200–232), and 0.1460.07 at +40 mV and 0.2960.17 at 240 mV (for triadin200–231).
doi:10.1371/journal.pone.0043817.g002
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Single Channel Recording and Analysis
Artificial planar bilayers separating two baths (cis and trans) were
formed as previously described [9,32]. Purified RyR1s (3–4.5 mg),
SR vesicles (,50 mg) or expressed RyR1 DM1,2,3 (3–4.5 mg) were
added to the cis solution so that the cytoplasmic surface of RyR1
faced the cis solution after incorporation into the lipid bilayer [9].
The composition of the incorporation solutions were as follows: cis:
230 mM CsMS, 20 mM CsCl, 1 mM CaCl2, and 10 mM TES
(pH 7.4); and trans: 30 mM CsMS, 20 mM CsCl, 1 mM CaCl2,
and 10 mM TES (pH 7.4). After incorporation of a channel, trans
[Cs+] was raised from 50 to 250 mM with the addition of 200 mM
CsMS and the cis solution was modified by the addition of 2 mM
ATP and ,4.5 mM BAPTA to achieve a final free [Ca2+] of
100 nM, determined using a Ca2+ electrode (Radiometer Analyt-
ical SAS, Villeurbanne, France). Peptides were added to the trans
chamber. Orientation of the incorporated RyR1 was confirmed by
characteristic responses to changes in cytoplasmic [Ca2+], ATP
and ruthenium red [34,35]. The data was filtered at 1 kHz and
sampled at 5 kHz.
Single channel parameters from 90–180 s of recording were
obtained using the Channel 2 program (developed by P.W. Gage
and M. Smith, John Curtin School of Medical Research,
Canberra, Australia). The threshold levels for channel opening
were set to exclude baseline noise at ,20% of the maximum
single-channel conductance, and open probability (Po), mean open
time (To), mean closed time (Tc) and open frequency (Fo) measured.
All electrical potentials are expressed as that of cytoplasmic
solution relative to the luminal solution. Single channel recordings
were obtained at +40 mV and 240 mV. These voltages were
chosen to ensure a large current flow through the channel, which
would maximize the signal to noise ratio, without easily breaking
the bilayer. Currents at both positive and negative potentials were
monitored to assess possible voltage dependent effects of the
peptide. Measurements were carried out at 2362uC.
Statistics
Average data are presented as mean 6 SEM. To reduce the
effects of variability in control parameters (PoCon, ToCon, TcCon,
FoCon), and to evaluate parameters after peptide addition (PoPep,
ToPep, TcPep, FoPep), data were expressed as the difference between
log10XPep and log10XCon for each channel (e.g., log10PoPep 2
log10PoCon). The difference from control was assessed with a paired
t-test. A P value of ,0.05 was considered significant.
Results
Secondary Structure of Triadin Peptides
Two peptides were used to assess the Trisk 95-RyR1 in-
teraction. One peptide (triadin200–232) contains a canonical KEKE
motif with 60.6% K/E/D residues. The other peptide (triadin200–
231) is missing the final residue of triadin200–232 which technically
puts it outside the definition of a KEKE motif (it only contains
57.6% K/E/D). Both peptides were assessed for their secondary
structure.
Kobayashi et al. [27] proposed that residues 210–224 of
a canine cardiac triadin-1 KEKE motif form a b strand to allow
triadin-1 to interact with CSQ2. The same KEKE motif is found
within residues 200–232 of Trisk 95 and may also employ
a b strand structure to bind the RyR1. If this is the case, the
triadin200–232 peptide may adopt a b strand structure and self
aggregate to display b-sheet secondary structure, as such structures
have been observed with peptides as short as 13 residues in length
[36,37]. Therefore, we investigated the structural profile of the
triadin200–231 and triadin200–232 peptides using circular dichroism
(CD). The CD spectra revealed that the secondary structure of
both peptides was disordered (Fig. 1A). Neither spectra display
peaks characteristic of either a-helical or b-sheet structure.
Disrupting the KEKE motif by shortening the peptide (to
triadin200–231) did not significantly alter its structure. The sequence
of the two peptides was identical apart from the lack of residue 232
in the truncated peptide. Thus, not unexpectedly, the loss of the
classically defined KEKE motif, did not affect the peptide’s
secondary structure.
Triadin Peptide Association with RyR1
The ability of the peptides to associate with RyR1 was
considered next. Biotinylated triadin200–232 or triadin200–231
peptide was coupled to immobilized streptavidin-agarose prior to
incubation with purified RyR1. The resultant peptide-protein
complex was eluted as described (Methods), and identified post
Western Blot by immunoprobing with anti-RyR1 and streptactin
(biotin probe). There was a substantial association between the
purified RyR1 and both the triadin200–232 and triadin200–231
peptides (Fig. 1B; lanes 4 and 5). No detectable RyR1 bound to the
streptavidin-agarose when the biotinylated triadin peptide was
absent (Fig. 1B; lane 1). Therefore, both peptides bound RyR1
despite being primarily unstructured, and they did so to the same
extent as full length Trisk 95 under the same conditions [18].
Figure 3. Triadin peptide modulates purified RyR1 single
channel open time, closed time and closed frequency. (A)
Average data for open probability (Po) in presence of triadin
200–232 and
triadin200–231 (n = 10), data from both peptides combined (see results
text, collectively termed triadin peptide, n = 11–20) for each of the
following parameters; open time (To), close time (Tc) and open
frequency (Fo), collected at 240 mV and +40 mV. All data is expressed
as relative mean data (Log rel (parameter)). Relative mean Po (log rel Po)
is the average of differences between the log10 of the Po in the
presence of either 63 nM or 252 nM triadin peptide (log10 PoPep) and
log10 of the control Po (log10 PoCon) for each channel. Log rel To is log10
ToPep-log10ToCon, log rel Tc is log10 TcPep-log10 TcCon and log rel Fo is log10
FoPep-log10 FoCon. (B) [
3H]ryanodine binding to purified RyR1 in the
absence and presence of 63 nM of triadin peptide. [3H]ryanodine
binding is measured as pmol ryanodine/mg RyR1. Data is expressed
relative to binding recorded in the absence of peptides (rel ryanodine
binding). Significance (p#0.05) is indicated for each concentration
compared to activity recorded prior to addition of peptide (*).
doi:10.1371/journal.pone.0043817.g003
Triadin-RyR Interaction Domain
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Regulation of Purified RyR Channel Activity by Triadin
Peptides
It is not known which RyR1 binding regions of Trisk 95 [17,22]
are responsible for the protein’s robust activation of RyR1. To test
our hypothesis that residues 200–232 in Trisk 95 contribute to
RyR1 modulation, we examined the effects of the triadin200–232
and triadin200–231 peptides on purified RyR1 activity using the
single channel lipid bilayer technique. Purified RyR1 channels
were incorporated into lipid bilayers in the presence of 100 nM cis
Ca2+ and 1 mM trans Ca2+. After baseline RyR1 activity was
recorded, the peptides were added at a concentration of 63 nM to
the trans chamber, which is equivalent to the molar concentration
of full length Trisk 95 and cardiac triadin-1 used in previous lipid
bilayer studies [24,25]. To determine whether this was a saturating
concentration of peptide, the RyR1 response to a 4-fold greater
peptide concentration (252 nM) was also tested.
Addition of either triadin200–232 or triadin200–231 peptide
resulted in a significant increase in RyR1 activity. This activation
was sustained over the lifetime of the bilayer, as demonstrated by
measuring open probability (Po) over the course of the experiment
(Fig. 2A). There was no significant difference between the Po
increase induced by the two peptides (p = 0.132, Fig. 2B & C, 3A).
The triadin200–232 peptide caused a 1.4960.11-fold increase in Po
(in the presence of peptide relative to absence of peptide), while
triadin200–231 caused a 1.860.15-fold increase. There was no
significant difference in the degree of activation evoked by either
peptide at 240 mV and +40 mV (Fig. 2B), or at 63 nM and
252 nM (Fig. 2, 3A). Thus maximal RyR1 activation was achieved
by 63 nM peptide. As both peptides mediated similar RyR1
activation, data from the two peptides is combined and the
peptides collectively referred to as triadin peptide in all subsequent
experiments. Combined lipid bilayer data demonstrated the
triadin peptide increases Po via a significant abbreviation of
channel closed time, and significant increases in both the open
time and the frequency of openings (Fig. 3A). Results obtained
using [3H]ryanodine binding supported the single channel data.
The addition of triadin peptide to purified RyR1 evoked
a significant 1.7360.21-fold increase in [3H]ryanodine binding
(Fig. 3B), which indicates increased channel activity and is
consistent with the single channel data.
Comparison of the regulatory effects of full length Trisk 95
(which was isolated and purified from rabbit skeletal muscle) and
the triadin peptide reveals that both caused a similar increase in Po
(Table 1) and increase in [3H]ryanodine binding [18]. Therefore,
Table 1. Channel open probability parameter values for native and purified RyR1 measured in the presence and absence of 63 nM
Triadin peptide and 63 nM full length Trisk 95.
Po
RyR1 2 triadin peptide + triadin peptide Fold change n 2Trisk 95 + Trisk 95 Fold change n
Native 0.77160.054 0.85660.053 1.12 6 – – – –
Purified 0.27360.057 0.40260.074* 1.68* 20 0.11160.017 0.20760.02* 1.86* 40
The average open probability (Po) values calculated from lipid bilayer experiments are shown. Po for each channel type and presence or absence of peptide/Trisk 95 is
measured from 90 s of activity at both +40 mV and 240 mV (pooled). The fold change is the Po value after trans addition of triadin peptide or full length Trisk 95,
relative to Po in the absence of triadin peptide/Trisk 95. Trisk 95 was isolated from rabbit skeletal muscle and these data (in italics) have been previously published in [13]
and are included here for comparison. Significant (p#0.05) differences in Po upon addition of triadin peptide or Trisk 95 are indicated for each condition compared to its
control (*).
doi:10.1371/journal.pone.0043817.t001
Figure 4. Triadin peptide does not activate mutant or native RyR1, or when its RyR1 binding site is blocked. (A–B) 3 s traces of RyR1
channel activity at240 mV. Channels are opening downwards from zero current (c, continuous line) to maximum open conductance (o, broken line).
(A) RyR1 DM1,2,3 mutants (with Trisk 95 binding residues mutated) in absence of triadin peptide and in the presence of trans 63 nM and 252 nM
peptide. (B) Native RyR1 in the absence and presence of trans 63 nM triadin peptide. Average open probability (Po) of data, collected at 240 mV and
+40 mV (n= 6–10) is displayed below each trace. (C) [3H]ryanodine binding to purified RyR with triadin binding blocking peptide (RyR14871–4910 ) in
the absence and presence of 63 nM triadin peptide. [3H]ryanodine binding is measured as pmol ryanodine/mg RyR1 and data is expressed relative to
binding recorded in the absence of either peptide (rel ryanodine binding). All values are presented as relative to control. Asterisks (*) indicate
a significant difference (p#0.05) in binding from RyR1 control (no peptide); crosshatch (#) indicates a significant difference (p#0.05) in binding from
RyR1 in the presence of RyR14871–4910.
doi:10.1371/journal.pone.0043817.g004
Triadin-RyR Interaction Domain
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the triadin peptide (specifically residues 200–231) replicates the
effect of Trisk 95 on RyR1. It is interesting to note that any post-
translational modification (such as disulfide formation and
glycosylation) of Trisk 95 from rabbit skeletal muscle is not
present in the triadin peptide and therefore appears unimportant
for RyR1 activation by Trisk 95.
Triadin Peptide Regulation of RyR1 with Mutated or
Occupied Trisk 95 Binding Site
Three residues of RyR1 (D4878, D4907, and E4908) are critical for
the protein’s ability to interact with Trisk 95. When these RyR1
residues are mutated to alanines, Trisk 95 no longer physically or
functionally interacts with RyR1 [18,23]. In a control experiment,
the RyR1 mutant construct (RyR1 DM1,2,3) containing the three
critical mutations (D4878A, D4907A and E4908A) was incorpo-
rated into a lipid bilayer. There was no significant change in
channel activity after addition of either 63 nM or 252 nM trans
triadin peptide (Fig. 4A). The inability of triadin peptide to activate
the RyR1 DM1,2,3 mutant indicates that it requires the same
residues as the Trisk 95 protein to bind to and activate RyR1.
A similar conclusion was reached when triadin peptide was
added to native RyR1 which retains endogenous Trisk 95 (as well
as junctin and CSQ1). SR vesicles (containing native RyR1) were
incorporated into lipid bilayers and 63 nM triadin peptide was
added to the trans chamber (Fig. 4B). Triadin peptide did not
activate RyR1 as strongly in the presence of endogenous Trisk 95
as in its absence (compare Fig. 2B and 4B). The fact that triadin
peptide did not produce the same degree of RyR1 activation when
endogenous Trisk 95 is present, is consistent with the peptide
associating with the same site as Trisk 95 on the RyR1. This,
together with the data from the RyR1 DM1,2,3 mutant, provides
strong evidence that residues 200–231 of Trisk 95 replicates all the
nuances of RyR1 regulation displayed by the full length protein
[13].
Blocking the RyR1 Binding Site on Trisk 95
We examined the effect of blocking the RyR1 binding site on
triadin using a RyR1 peptide (with the sequence of the triadin
binding site and surrounding residues) on [3H]ryanodine binding.
Triadin peptide was pre-incubated with a 10x greater concentra-
tion of RyR14871–4910 peptide, prior to addition to purified RyR1.
The RyR14871–4910 peptide should saturate all residues on the
triadin peptide which interact with RyR1 and we expected to see
no additional change in [3H]ryanodine binding when the
combined triadin peptide plus RyR14871–4910 was added to
purified RyR1. RyR14871–4910 alone did not influence [3H]ryano-
dine binding (Fig. 4C). Curiously, we found triadin peptide in fact
reduced [3H]ryanodine binding when pre-incubated with
RyR14871–4910, indicating RyR1 inhibition (Fig. 4C). This in-
hibition could be due to residues within the triadin peptide that did
not interact with RyR14871–4910 (i.e. not involved in the specific
Trisk 95-RyR1 interaction) binding to RyR1. This binding may
have been to luminal or cytoplasmic domains of RyR1 as peptides
can access both the cytoplasmic and luminal faces of RyR1 in the
[3H]ryanodine binding assay. In lipid bilayers, the peptides can
only access the luminal face of RyR1, and there was no inhibitory
effect on the channel when the Trisk 95 binding sites on RyR1 was
mutated or occupied by endogenous Trisk 95 (Fig. 4A, B). Taken
together, these results show that the triadin peptide inhibits RyR1
only when (i) the luminal RyR1 binding site of the peptide is
unavailable and (ii) when sites on the cytoplasmic side of the RyR1
are exposed. Blocking the critical RyR1 binding residues on the
triadin peptide prevented the stimulating effect of the triadin
peptide on RyR1 (Fig. 4C), consistent with Trisk 95 residues 200–
231 forming the activating domain for RyR1.
Discussion
In this study we show that two Trisk 95 peptides, corresponding
to residues 200–232 (triadin200–232) and 200–231 (triadin200–231),
bind to and activate RyR1. The truncated peptide did not lose the
ability to regulate RyR1 despite no longer containing a true
KEKE motif. Both peptides significantly increased RyR1 Po in
lipid bilayer studies, and the same is inferred from [3H]ryanodine
binding data. The degree of RyR1 activation caused by the
peptides replicates that by full length Trisk 95 under identical
experimental conditions [13,18]. The peptides do not activate
RyR1 when their Trisk 95 binding site is mutated or occupied.
Our findings indicate that both triadin peptides are intrinsically
disordered, and suggest that neither a rigid secondary structure
nor an artificially defined KEKE motif determine the peptides’
ability to bind to and activate RyR1. Kobayashi et al [27]
hypothesized that specific residues and structure are important for
maintaining the triadin-1/CSQ2 interaction. Our results indicate
that structure is not important and that specific residues between
200–231 are responsible for binding to RyR1 and activating the
channel.
As Trisk 95 residues 200–231 are sufficient to mimic the
activation of RyR1 by full length Trisk 95, it seems unlikely that
the other luminal region on Trisk 95 shown to bind the RyR1 with
high affinity (residues 267–279; [22]) contributes to the functional
effects of the RyR1-Trisk 95 association. In addition, the
hydrophobic nature of Trisk 95 residues 267–279 suggests they
are unlikely to form binding partners for the acidic D4878, D4907
and E4908 residues on RyR1, whereas the basic residues of Trisk
95 200–231 would provide appropriate binding partners. That
said, we cannot exclude the possibility that residues 267–279 help
stabilize the Trisk 95-RyR1 interaction in vivo. In fact, Trisk 95
contains a cysteine at residue 270. Earlier studies suggest that
under certain circumstances C270 may form a disulfide bond with
RyR1 (or other SR proteins) providing a stabilizing thiol link
between the two proteins [38]. Indeed, reducing agents are
routinely used in our lab to dissociate Trisk 95 from RyR1.
Current dogma holds that in skeletal muscle, Trisk 95 and
junctin remain closely and simultaneously associated with both
CSQ1 and the RyR1. However, junctin alone supports the ability
of CSQ1 to inhibit RyR1 activity [13]. Trisk 95 does not mediate
the functional coupling between RyR1 and CSQ1. In vitro studies
of purified proteins indicate that Trisk 95 binds to RyR1 and to
CSQ1 individually [14,16,17,18], but simultaneous binding of
CSQ1 and RyR1 to Trisk 95 has not been demonstrated. We have
shown that residues within 200–231 are critical for Trisk 95
association with, and its functional influence on, RyR1. Based on
the CSQ2-triadin-1 association in canine cardiac muscle [27], it is
predicted that CSQ1 would bind to Trisk 95 residues 218–232 in
rabbit. Therefore, the binding sites on Trisk 95 for RyR1 and
CSQ1 may overlap such that both proteins would be unlikely to
associate with Trisk 95 simultaneously. This could explain why
CSQ1 induced RyR1 inhibition is mediated by junctin alone [13].
If Trisk 95 does not bind to the RyR1 and to CSQ1
simultaneously, it is tempting to speculate that domain swapping
between CSQ1 and RyR1 for the binding site on Trisk 95 may
contribute to the modulation of SR Ca2+ release during EC
coupling. The affinity between CSQ1 and Trisk 95 becomes lower
as the [Ca2+] increases [12,14]. So, when the SR store [Ca2+] is
high (i.e. in resting muscle fibres), Trisk 95 may preferentially bind
to RyR1 (and not CSQ1), activating the channel to facilitate Ca2+
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release. The drop in SR free Ca2+ during contraction would
promote Trisk 95 association with CSQ1, relieving Trisk 95
activation of RyR1 and thus conserving the store Ca2+ load and
reducing SR Ca2+ leak. This hypothesis is consistent with the role
suggested for Trisk 95 in EC-coupling, [18], whereby the luminal
Trisk 95-RyR1 interaction activates the RyR1 channel in response
to the depolarization-evoked signal from the DHPR.
We have provided novel evidence that residues 200–231 of
Trisk 95 mediate the RyR1 activation by full length Trisk 95.
Furthermore, we found that these residues were important despite
the lack of a b-strand or helical secondary structure. Therefore the
residues within 200–231 of Trisk 95, and not their specific
structure, are responsible for RyR1 activation by full length Trisk
95. It seems plausible that basic residues within 200–231 will form
binding partners for D4878, D4907 and E4908 of RyR1. Future
experiments will be performed to identify which individual
residues between Trisk 95 200–231 are responsible for binding
to RyR1 and activating the channel.
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